Effect of Vardenafil on Blood Pressure Profile of Patients With Erectile Dysfunction Concomitantly Treated With Doxazosin Gastrointestinal Therapeutic System for Benign Prostatic Hyperplasia

Journal of Urology

Volumn 180, Issue 3, 2008, Pages 1042-1046

  Ng, Chi Fai ^a   Wong, Annie ^a   Cheng, Chi Wai ^a   Chan, Eddie Shu Yin ^a   Wong, Hon Ming ^a   Hou, See Ming ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

adrenergic alpha antagonists; erectile dysfunction; phosphodiesterase inhibitors; prostatic hyperplasia

Indexed keywords

ALFUZOSIN; DOXAZOSIN; SILDENAFIL; TADALAFIL; TAMSULOSIN; TERAZOSIN; VARDENAFIL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLURRED VISION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HEART HEMODYNAMICS; HEART PALPITATION; HUMAN; HYPOTENSION; MALAISE; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TINNITUS; TREATMENT OUTCOME;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; ANALYSIS OF VARIANCE; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DOXAZOSIN; DRUG THERAPY, COMBINATION; ERECTILE DYSFUNCTION; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PLACEBOS; PROSTATIC HYPERPLASIA; SULFONES; TREATMENT OUTCOME; TRIAZINES;

EID: 48649100128     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.05.052     Document Type: Article

References (20)

1. Rosen R., Altwein J., Boyle P., Kirby R.S., Lukacs B., Meuleman E., et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44 (2003) 637
2. McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 97 (2006) 23
3. Kaplan S.A., Gonzalez R.R., and Te A.E. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51 (2007) 1717
4. De Rose A.F., Giglio M., Traverso P., Lantieri P., and Carmignani G. Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy. Int J Impot Res 14 (2002) 50
5. Kloner R.A., Jackson G., Emmick J.T., Mitchell M.I., Bedding A., Warner M.R., et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil, and 2 alpha-blockers, doxazosin and tamsulosin, in healthy normotensive men. J Urol 172 (2004) 1935
6. Giuliano F., Kaplan S.A., Cabanis M.J., and Astruc B. Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. Urology 67 (2006) 1199
7. Kloner R.A. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am J Cardiol 96 (2005) 42M
8. Auerbach S.M., Gittelman M., Mazzu A., Cihon F., Sundaresan P., and White W.B. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology 64 (2004) 998
9. Chung M., Vashi V., Puente J., Sweeney M., and Meredith P. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol 48 (1999) 678
10. Rosen R.C., Cappelleri J.C., Smith M.D., Lipsky J., and Peňa B.M. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 11 (1999) 319
11. Klotz T., Sachse R., Heidrich A., Jockenhövel F., Rohde G., Wensing G., et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 19 (2001) 32
12. Kostis J.B., Jackson G., Rosen R., Barrett-Connor E., Billups K., Burnett A.L., et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 96 (2005) 313
13. Djavan B., Chapple C., Milani S., and Marberger M. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 64 (2004) 1081
14. Rampin O., and Giuliano F. Central control of the cardiovascular and erection systems: possible mechanisms and interactions. Am J Cardiol 86 (2000) 19F
15. Burchardt M., Burchardt T., Baer L., Kiss A.J., Pawar R.V., Shabsigh A., et al. Hypertension is associated with severe erectile dysfunction. J Urol 164 (2000) 1188
16. Zusman R.M., Prisant L.M., and Brown M.J. Effect of sidenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. J Hypertens 18 (2000) 1865
17. van Ahlen H., Wahle K., Kupper W., Yassin A., Reblin T., and Neureither M. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med 2 (2005) 856
18. Tinel H., Stelte-Ludwig B., Hutter J., and Sandner P. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 98 (2006) 1259
19. McVary K.T., Roehrborn C.G., Kaminetsky J.C., Auerbach S.M., Wachs B., Young J.M., et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177 (2007) 1401
20. McConnell J.D., Roehrborn C.G., Bautista O.M., Andriole Jr. G.L., Dixon C.M., Kusek J.W., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387